Glimepiride is the third generation of sulfonylurea long-acting antidiabetic drugs. The main mechanism of its hypoglycemic effect is stimulating the islets of Langerhans. β The cells secrete insulin and partially improve the sensitivity of surrounding tissues to insulin. The binding and dissociation rate of this product with insulin receptor is faster than that of glibenclamide, and less serious hypoglycemia is caused.